Subtopic Deep Dive

← Protein Kinase Regulation and GTPase Signaling

Ras Signaling Pathways
Research Guide

What is Ras Signaling Pathways?

Ras signaling pathways encompass the molecular mechanisms by which Ras GTPases cycle between inactive GDP-bound and active GTP-bound states to activate downstream effectors like RAF, PI3K, and RalGDS in cell proliferation and survival.

Ras proteins integrate signals from receptor tyrosine kinases to trigger MAPK/ERK, PI3K/AKT, and other cascades critical for oncogenesis. Oncogenic mutations lock Ras in the GTP-bound state, driving 30% of human cancers. Over 30,000 papers explore Ras effectors, inhibitors, and therapeutic targeting (Downward, 2003; Wilhelm et al., 2004).

Curated Papers

Key Challenges

Why It Matters

Mutated Ras drives 30% of human cancers, including pancreatic and lung adenocarcinomas, making its RAF/MEK/ERK pathway a prime oncology target. Sorafenib (BAY 43-9006) inhibits Raf-1 and receptor tyrosine kinases, showing broad antitumor activity in preclinical models (Wilhelm et al., 2004, 3985 citations). PD098059 specifically blocks MEK activation, enabling dissection of MAPK roles in proliferation (Alessi et al., 1995, 3421 citations). Targeting these pathways supports precision therapies, as reviewed comprehensively (Downward, 2003; Dhillon et al., 2007).

Key Research Challenges

Drugging Oncogenic Ras

Ras lacks deep pockets for small-molecule binding, complicating direct inhibition despite frequent mutations. Indirect targeting via effectors like RAF yields resistance (Downward, 2003). Over 3000 papers document failures in clinical translation (Roberts and Der, 2007).

Effector Pathway Crosstalk

Ras activates multiple effectors (RAF, PI3K, RalGDS), causing compensatory signaling upon single-pathway inhibition. MAPK inhibitors like PD098059 reveal feedback loops (Alessi et al., 1995). Kinase inhibitor selectivity profiling shows off-target effects (Bain et al., 2007).

Resistance Mechanisms

Tumors evolve resistance to RAF/MEK inhibitors through RAS reactivation or parallel pathways. Sorafenib resistance involves RTK upregulation (Wilhelm et al., 2004). Modeling requires multi-omics integration across 2500+ studies (Dhillon et al., 2007).

Essential Papers

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · 2004 · Cancer Research · 4.0K citations

Abstract The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation and angiogenesis. The novel bi-aryl urea BAY 43-9006 is a potent inhibitor of Raf-1, a member of the RAF/...

The small GTP-binding protein rac regulates growth factor-induced membrane ruffling

Anne J. Ridley, Hugh F. Paterson, Caroline L. Johnston et al. · 1992 · Cell · 3.6K citations

PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo

Dario R. Alessi, Ana Cuenda, Philip Cohen et al. · 1995 · Journal of Biological Chemistry · 3.4K citations

PD 098059 has been shown previously to inhibit the dephosphorylated form of mitogen-activated protein kinase kinase-1 (MAPKK1) and a mutant MAPKK1(S217E,S221E), which has low levels of constitutive...

Targeting RAS signalling pathways in cancer therapy

Julian Downward · 2003 · Nature reviews. Cancer · 3.2K citations

MAP kinase signalling pathways in cancer

Amardeep S. Dhillon, Suzanne Hagan, Oliver Rath et al. · 2007 · Oncogene · 3.0K citations

MAPK signal pathways in the regulation of cell proliferation in mammalian cells

Wei Zhang, Hui-Tu Liu · 2002 · Cell Research · 2.8K citations

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Patrick J. Roberts, Channing J. Der · 2007 · Oncogene · 2.8K citations

Reading Guide

Foundational Papers

Start with Downward (2003) for Ras-cancer overview (3203 cites), Ridley et al. (1992) for GTPase mechanisms (3641 cites), then Wilhelm et al. (2004) for RAF targeting (3985 cites) to build pathway intuition.

Recent Advances

Dhillon et al. (2007, 2958 cites) on MAPK in cancer; Roberts and Der (2007, 2766 cites) on therapeutic cascades; Bain et al. (2007, 2489 cites) for inhibitor profiling.

Core Methods

GTP/GDP cycling assays; RAF/MEK inhibitors (PD098059, sorafenib); kinase selectivity screens; mammalian cell proliferation models via MAPK blockade.

How PapersFlow Helps You Research Ras Signaling Pathways

Discover & Search

Research Agent uses searchPapers('Ras RAF MEK inhibitors cancer') to retrieve 50+ papers including Wilhelm et al. (2004), then citationGraph to map downstream citations from Downward (2003, 3203 cites), and findSimilarPapers for effector-specific variants like Ridley et al. (1992). exaSearch uncovers obscure GTPase-rac crosslinks.

Analyze & Verify

Analysis Agent applies readPaperContent on Wilhelm et al. (2004) to extract Raf-1 IC50 values, verifyResponse with CoVe to cross-check sorafenib's RAF/MEK specificity against Alessi et al. (1995), and runPythonAnalysis for dose-response curve fitting from inhibitor data using SciPy. GRADE grading scores evidence strength for clinical translation claims.

Synthesize & Write

Synthesis Agent detects gaps in Ras inhibitor resistance literature via contradiction flagging across Roberts and Der (2007) and Dhillon et al. (2007); Writing Agent uses latexEditText for pathway diagrams, latexSyncCitations to integrate 20+ refs, and latexCompile for camera-ready reviews. exportMermaid generates interactive RAF/MEK cascades.

Use Cases

"Analyze PD098059 MEK inhibition kinetics from Alessi 1995 and plot IC50 curves"

Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib IC50 fitting) → matplotlib plot of dose-response with statistical fit (R²=0.98).

"Write LaTeX review of Ras-RAF inhibitors with citations and pathway figure"

Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Wilhelm/Downward) → latexCompile + exportMermaid (RAF cascade diagram) → PDF with 15 citations.

"Find GitHub repos modeling Ras signaling from recent papers"

Research Agent → searchPapers('Ras MAPK simulation') → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable SBML models of ERK phosphorylation.

Automated Workflows

Deep Research workflow scans 50+ Ras papers via searchPapers → citationGraph → structured report ranking inhibitors by efficacy (Wilhelm scores highest). DeepScan's 7-step chain verifies MEK specificity: readPaperContent (Alessi) → CoVe → GRADE A rating. Theorizer generates hypotheses on Ras-rac crosstalk from Ridley (1992) + modern effectors.

Try Doxa for Ras Signaling Pathways Research

Frequently Asked Questions

What defines Ras signaling pathways?

Ras GTPases cycle GDP/GTP to activate effectors like RAF/MEK/ERK and PI3K/AKT upon RTK stimulation, driving proliferation (Downward, 2003).

What are key methods for studying Ras pathways?

Inhibitors like PD098059 block MEK activation (Alessi et al., 1995); sorafenib targets RAF (Wilhelm et al., 2004); selectivity profiling uses kinase panels (Bain et al., 2007).

What are seminal papers on Ras signaling?

Downward (2003, 3203 cites) reviews cancer targeting; Wilhelm et al. (2004, 3985 cites) validates sorafenib on RAS/RAF; Ridley et al. (1992, 3641 cites) links rac GTPases.

What open problems persist in Ras research?

Direct Ras inhibition remains elusive; resistance to RAF/MEK drugs via feedback loops unaddressed (Roberts and Der, 2007); effector crosstalk needs better models.